Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous rituximab with CHOP in previously untreated diffuse large B-cell lymphoma
NL-OMON41547Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Roche. Primary endpoint: Complete response rate including complete response unconfirmed. Started Jan 2013; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON41547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41547.